drugset
drugset / Trial / NCT06846463

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

NCT06846463 ↗

Phase 2 Recruiting 21 enrolled Virginia Commonwealth University
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

Timeline

Start
2025-05-27
Primary completion
2029-07-31
Completion
2032-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 160 mg Oral
Subject Zanubrutinib Small molecule 320 mg Oral

Indications

diffuse large B-cell lymphoma